{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:55:40Z","timestamp":1789998940941,"version":"4.0.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.maturitas.2013.05.004","type":"journal-article","created":{"date-parts":[[2013,6,3]],"date-time":"2013-06-03T18:46:55Z","timestamp":1370285215000},"page":"335-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Fibromyalgia syndrome \u2013 Novel therapeutic targets"],"prefix":"10.1016","volume":"75","author":[{"given":"Jacob N.","family":"Ablin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Buskila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.maturitas.2013.05.004_bib0005","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1002\/art.11272","article-title":"Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors","volume":"48","author":"Giesecke","year":"2003","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1016\/j.maturitas.2013.05.004_bib0015","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3899\/jrheum.100594","article-title":"Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia","volume":"38","author":"Wolfe","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"5944","key":"10.1016\/j.maturitas.2013.05.004_bib0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/306686a0","article-title":"Evidence for a central component of post-injury pain hypersensitivity","volume":"306","author":"Woolf","year":"1983","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.maturitas.2013.05.004_bib0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.semarthrit.2007.09.003","article-title":"Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness","volume":"37","author":"Yunus","year":"2008","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"5","key":"10.1016\/j.maturitas.2013.05.004_bib0030","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/ACO.0b013e32833c348b","article-title":"Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states","volume":"23","author":"Yarnitsky","year":"2010","journal-title":"Current Opinion in Anesthesiology"},{"issue":"10","key":"10.1016\/j.maturitas.2013.05.004_bib0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-146-10-200705150-00006","article-title":"Narrative review: the pathophysiology of fibromyalgia","volume":"146","author":"Abeles","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0040","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.rdc.2009.05.008","article-title":"The significance of dysfunctions of the sleeping\/waking brain to the pathogenesis and treatment of fibromyalgia syndrome","volume":"35","author":"Moldofsky","year":"2009","journal-title":"Rheumatic Diseases Clinics of North America"},{"issue":"8","key":"10.1016\/j.maturitas.2013.05.004_bib0045","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.27497","article-title":"Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity","volume":"62","author":"Napadow","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1016\/j.maturitas.2013.05.004_bib0050","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1002\/art.34412","article-title":"Decreased intrinsic brain connectivity is associated with reduced clinical pain in fibromyalgia","volume":"64","author":"Napadow","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1016\/j.maturitas.2013.05.004_bib0055","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00482-012-1173-1","article-title":"Multicomponent therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline","volume":"26","author":"Arnold","year":"2012","journal-title":"Schmerz"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0060","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","article-title":"Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex","volume":"42","author":"Fink","year":"2002","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainres.2005.12.084","article-title":"Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice","volume":"1075","author":"Bian","year":"2006","journal-title":"Brain Research"},{"issue":"4","key":"10.1016\/j.maturitas.2013.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/sleep\/28.2.187","article-title":"A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo","volume":"28","author":"Hindmarch","year":"2005","journal-title":"Sleep"},{"issue":"4","key":"10.1016\/j.maturitas.2013.05.004_bib0080","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/art.22457","article-title":"Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"56","author":"Arnold","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1016\/j.maturitas.2013.05.004_bib0085","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.addr.2011.11.006","article-title":"Chemical properties of antiepileptic drugs (AEDs)","volume":"64","author":"Bialer","year":"2012","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"9","key":"10.1016\/j.maturitas.2013.05.004_bib0090","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1002\/art.20485","article-title":"A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder","volume":"50","author":"Arnold","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"1\u20133","key":"10.1016\/j.maturitas.2013.05.004_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.maturitas.2013.05.004_bib0100","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.pain.2008.02.024","article-title":"Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial","volume":"136","author":"Russell","year":"2008","journal-title":"Pain"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2013.05.004_bib0105","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.622","article-title":"A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia","volume":"19","author":"Vitton","year":"2004","journal-title":"Human Psychopharmacology"},{"issue":"9","key":"10.1016\/j.maturitas.2013.05.004_bib0110","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/art.27559","article-title":"Efficacy and safety of milnacipran 100mg\/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Arnold","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0115","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.080734","article-title":"The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Mease","year":"2009","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1016\/j.maturitas.2013.05.004_bib0120","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.clinthera.2008.11.009","article-title":"Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial","volume":"30","author":"Clauw","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"7","key":"10.1016\/j.maturitas.2013.05.004_bib0125","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.34390","article-title":"Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"64","author":"Arnold","year":"2012","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1016\/j.maturitas.2013.05.004_bib0130","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1111\/j.1460-9568.2007.05623.x","article-title":"Fibromyalgia patients show an abnormal dopamine response to pain","volume":"25","author":"Wood","year":"2007","journal-title":"European Journal of Neuroscience"},{"issue":"8","key":"10.1016\/j.maturitas.2013.05.004_bib0135","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.21191","article-title":"A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications","volume":"52","author":"Holman","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1016\/j.maturitas.2013.05.004_bib0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.rhu.0000081264.26484.e5","article-title":"Ropinirole, open preliminary observations of a dopamine agonist for refractory fibromyalgia","volume":"9","author":"Holman","year":"2003","journal-title":"Journal of Clinical Rheumatology"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/art.25062","article-title":"Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"62","author":"Distler","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1016\/j.maturitas.2013.05.004_bib0150","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/ard.2007.071522","article-title":"EULAR evidence-based recommendations for the management of fibromyalgia syndrome","volume":"67","author":"Carville","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"20","key":"10.1016\/j.maturitas.2013.05.004_bib0155","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1523\/JNEUROSCI.22-20-09086.2002","article-title":"Spinal neurons that possess the substance P receptor are required for the development of central sensitization","volume":"22","author":"Khasabov","year":"2002","journal-title":"Journal of Neuroscience"},{"issue":"11","key":"10.1016\/j.maturitas.2013.05.004_bib0160","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/art.1780371106","article-title":"Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome","volume":"37","author":"Russell","year":"1994","journal-title":"Arthritis and Rheumatism"},{"issue":"32","key":"10.1016\/j.maturitas.2013.05.004_bib0165","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.2009.21.8511","article-title":"Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"27","author":"Herrstedt","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.maturitas.2013.05.004_bib0170","unstructured":"GSK. GW679769. In: Fibromyalgia. ClinicalTrials gov; 2008. Available from: URL:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00264628 [cited 01.03.10]."},{"issue":"37","key":"10.1016\/j.maturitas.2013.05.004_bib0175","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1523\/JNEUROSCI.2849-07.2007","article-title":"Decreased central mu-opioid receptor availability in fibromyalgia","volume":"27","author":"Harris","year":"2007","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0180","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.37734","article-title":"Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels","volume":"65","author":"Younger","year":"2013","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.maturitas.2013.05.004_bib0185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1744-8069-6-22","article-title":"Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats","volume":"6","author":"Mattioli","year":"2010","journal-title":"Molecular Pain"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/glia.22363","article-title":"MicroRNAs are universal regulators of differentiation, activation, and polarization of microglia and macrophages in normal and diseased CNS","volume":"61","author":"Ponomarev","year":"2013","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0195","first-page":"192","article-title":"Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?","volume":"29","author":"Russo","year":"2008","journal-title":"Neuroendocrinology Letters"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/neu.20080","article-title":"The endogenous cannabinoid system and its role in nociceptive behavior","volume":"61","author":"Cravatt","year":"2004","journal-title":"Journal of Neurobiology"},{"issue":"8","key":"10.1016\/j.maturitas.2013.05.004_bib0205","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chemistry and Biodiversity"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0210","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","article-title":"Nabilone for the treatment of pain in fibromyalgia","volume":"9","author":"Skrabek","year":"2008","journal-title":"Journal of Pain"},{"issue":"2","key":"10.1016\/j.maturitas.2013.05.004_bib0215","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","article-title":"The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial","volume":"110","author":"Ware","year":"2010","journal-title":"Anesthesia and Analgesia"},{"key":"10.1016\/j.maturitas.2013.05.004_bib0220","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/827290","article-title":"Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey","author":"Weber","year":"2009","journal-title":"Anesthesiology Research and Practice"},{"issue":"7","key":"10.1016\/j.maturitas.2013.05.004_bib0225","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ncprheum0826","article-title":"Are cannabinoids a new treatment option for pain in patients with fibromyalgia?","volume":"4","author":"Staud","year":"2008","journal-title":"Nature Clinical Practice Rheumatology"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0230","first-page":"145","article-title":"Low growth hormone secretion in patients with fibromyalgia \u2013 a preliminary report on 10 patients and 10 controls","volume":"25","author":"Bagge","year":"1998","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1016\/j.maturitas.2013.05.004_bib0235","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0002-9343(97)00351-3","article-title":"A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia","volume":"104","author":"Bennett","year":"1998","journal-title":"American Journal of Medicine"},{"issue":"9","key":"10.1016\/j.maturitas.2013.05.004_bib0240","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1210\/jc.2010-0061","article-title":"High prevalence of growth hormone deficiency in severe fibromyalgia syndromes","volume":"95","author":"Cuatrecasas","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"7","key":"10.1016\/j.maturitas.2013.05.004_bib0245","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.pain.2012.02.012","article-title":"Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia","volume":"153","author":"Cuatrecasas","year":"2012","journal-title":"Pain"},{"issue":"8","key":"10.1016\/j.maturitas.2013.05.004_bib0250","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1523\/JNEUROSCI.12-08-03025.1992","article-title":"The role of NMDA and non-NMDA excitatory amino acid receptors in the excitation of primate spinothalamic tract neurons by mechanical, chemical, thermal, and electrical stimuli","volume":"12","author":"Dougherty","year":"1992","journal-title":"Journal of Neuroscience"},{"issue":"5472","key":"10.1016\/j.maturitas.2013.05.004_bib0255","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1126\/science.288.5472.1765","article-title":"Neuronal plasticity: increasing the gain in pain","volume":"288","author":"Woolf","year":"2000","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.maturitas.2013.05.004_bib0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jpain.2005.01.357","article-title":"Effects of the N-methyl-d-aspartate receptor antagonist dextromethorphan on temporal summation of pain are similar in fibromyalgia patients and normal control subjects","volume":"6","author":"Staud","year":"2005","journal-title":"Journal of Pain"},{"issue":"6","key":"10.1016\/j.maturitas.2013.05.004_bib0265","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jpain.2005.12.010","article-title":"The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients","volume":"7","author":"Cohen","year":"2006","journal-title":"Journal of Pain"},{"issue":"3","key":"10.1016\/j.maturitas.2013.05.004_bib0270","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0304-3959(99)00308-5","article-title":"Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients","volume":"85","author":"Graven-Nielsen","year":"2000","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.maturitas.2013.05.004_bib0275","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jpain.2006.01.457","article-title":"A reconsideration of the relevance of systemic low-dose ketamine to the pathophysiology of fibromyalgia","volume":"7","author":"Wood","year":"2006","journal-title":"Journal of Pain"},{"issue":"8","key":"10.1016\/j.maturitas.2013.05.004_bib0280","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00259-007-0392-7","article-title":"Predictive value of brain perfusion SPECT for ketamine response in hyperalgesic fibromyalgia","volume":"34","author":"Guedj","year":"2007","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0285","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","article-title":"Mechanism of action of memantine","volume":"6","author":"Johnson","year":"2006","journal-title":"Current Opinion in Pharmacology"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1745-6215-14-3","article-title":"Evaluation of the efficacy of memantine in the treatment of fibromyalgia: study protocol for a doubled-blind randomized controlled trial with six-month follow-up","volume":"14","author":"Olivan-Blazquez","year":"2013","journal-title":"Trials"},{"issue":"5","key":"10.1016\/j.maturitas.2013.05.004_bib0295","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejpain.2010.09.013","article-title":"A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia","volume":"15","author":"Vergne-Salle","year":"2011","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.maturitas.2013.05.004_bib0300","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1080\/03009740410007104","article-title":"Intravenous treatment of fibromyalgia with the 5-HT3 receptor antagonist tropisetron in a rheumatological practice","volume":"Suppl. 119","author":"Tolk","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"11","key":"10.1016\/j.maturitas.2013.05.004_bib0305","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00296-007-0406-6","article-title":"5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome","volume":"27","author":"Seidel","year":"2007","journal-title":"Rheumatology International"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0310","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.24142","article-title":"Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"60","author":"Russell","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"6","key":"10.1016\/j.maturitas.2013.05.004_bib0315","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/annrheumdis-2011-200418","article-title":"Sodium oxybate therapy provides multidimensional improvement in fibromyalgia: results of an international phase 3 trial","volume":"71","author":"Spaeth","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0320","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2710.2010.01233.x","article-title":"The evolving understanding of the analgesic mechanism of action of flupirtine","volume":"37","author":"Raffa","year":"2012","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"5","key":"10.1016\/j.maturitas.2013.05.004_bib0325","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJMoa041292","article-title":"Modafinil for excessive sleepiness associated with shift-work sleep disorder","volume":"353","author":"Czeisler","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.maturitas.2013.05.004_bib0330","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.rhu.0000255801.32408.6e","article-title":"Modafinil treatment for fatigue associated with fibromyalgia","volume":"13","author":"Schwartz","year":"2007","journal-title":"Journal of Clinical Rheumatology"},{"issue":"4","key":"10.1016\/j.maturitas.2013.05.004_bib0335","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1176\/jnp.13.4.530","article-title":"Modafinil in fibromyalgia treatment","volume":"13","author":"Schaller","year":"2001","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"7\u20138","key":"10.1016\/j.maturitas.2013.05.004_bib0340","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1345\/aph.1M736","article-title":"Armodafinil for fibromyalgia fatigue","volume":"44","author":"Schwartz","year":"2010","journal-title":"Annals of Pharmacotherapy"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512213001527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512213001527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:58:00Z","timestamp":1759913880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512213001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0378512213001527"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2013.05.004","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibromyalgia syndrome \u2013 Novel therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2013.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}